Drug intelligence / Profile preview

undisclosed cardiometabolic drug

Development stage: Preclinical
Lead developer: Korro Bio
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

The undisclosed cardiometabolic drug is a program being developed through a collaboration between Korro Bio and Novo Nordisk. It leverages Korro Bio's proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform. This platform is designed to utilize oligonucleotides to induce specific changes in messenger RNA (mRNA) encoding proteins, thereby modulating protein function without altering the underlying DNA genome. This approach aims to provide a pharmacologically titratable and transient genetic medicine, potentially enabling the targeting of previously undruggable pathways for cardiometabolic diseases such as obesity, diabetes, and cardiovascular diseases. Korro Bio is responsible for advancing the programs through preclinical development, with Novo Nordisk taking over for subsequent clinical studies.

Other names: RNA editing product candidates for two undisclosed targets

Targets

ADAR (Adenosine deaminases acting on RNA (ADAR) family)

Beyond the preview

Go deeper on undisclosed cardiometabolic drug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on undisclosed cardiometabolic drug.

Explore the full profile